Skip to main content
Premium Trial:

Request an Annual Quote

BARDA Awards $51.9M to DNAe to Develop Rapid Diagnostics

NEW YORK (GenomeWeb) – The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority has awarded a $51.9 million contract to London-based DNA Electronics to develop semiconductor-based next-generation sequencing diagnostics for antimicrobial resistant infections and influenza, the company said today.

Under the auspices of the project, entitled Pathogen Identification from Specimen via Capture Extraction and Sequencing, DNAe will complete development and validation of its Genalysis platform. It will also submit its tests for US Food and Drug Administration clearance.

"Unlike existing sequencing devices, the platform operates 'push button' directly from raw clinical specimens such as blood or swabs, delivering a clinically-relevant report for the physician," Sam Reed, president of DNAe's US office, said in a statement. Users do not have to be specially trained in sequencing, Reed added, "enabling [the platform] to be used in a wide range of near-to-patient clinical environments."

The company's first product will be a diagnostic test for sepsis. DNAe said the test is in late stage development and testing and will launch in 2018.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.